 |
 |
|
 |
||
 |
 |
|
 |
|
|
Last Updated: 3/17/2010
| Lisa A. Carey, M.D.
Associate Professor |  |
Clinical Interests
Dr. Carey is board-certified in both Internal Medicine and Medical Oncology. Her clinical interest is in breast cancer, and she is the Medical Director of the UNC Breast Center.
Research Interests
Dr. Carey's research interests also focus upon breast cancer, including examination of different subtypes of breast cancer, evaluation of new chemotherapy agents in early breast cancer, and examination of tumor characteristics that predict response to therapy.
Dr. Carey has worked extensively with scientists across Lineberger Comprehensive Cancer Center and the UNC Gillings Global School of Public Health to better understand and characterize the molecular subtypes of breast cancer so that we may develop better prevention and treatment strategies. With Drs. Perou and Millikan, she identified the elevated risk of the poor-prognosis basal-like breast cancer subtype in young African-American women. She is a world-wide expert in triple negative breast cancer, and led the first trial looking at a new drug regimen in this breast cancer subtype. She is now the leader of a group of UNC clinician researchers using a variety of new drugs in different molecular subtypes of breast cancer based upon biologic information learned from scientists at Lineberger.
For example, the members of the UNC Breast Center have a long commitment to improving treatment of early (nonmetastatic) breast cancer, and have been early investigators in the use of neoadjuvant, or preoperative, chemotherapy for breast cancer. In part based upon work performed at UNC, we now know that women do just as well if their chemotherapy is given before surgery as after, however the chemotherapy-first approach means that they are more likely to save their breast. In addition, with preoperative therapy it is possible to tell if the drugs are working since the tumor is still measurable when the chemotherapy is given first. Part of Dr. Carey's clinical research program investigates new drugs and combination of drugs in preoperative therapy. As part of this neoadjuvant chemotherapy program, she is involved in several studies, including a multiinstitutional trial sponsored by the National Cancer Institute, of genetic and molecular markers in breast cancer as predictors of response to chemotherapy, and she is the lead investigator of a national study of new drug combinations in HER2-positive breast cancer.
Dr. Carey is also the principal investigator of a highly collaborative study examining genes that might interact with other genes or with the environment to impact on a woman's risk of developing breast cancer.
Recent Accomplishments and Honors
For her work, she was awarded a Doris Duke Clinical Scientist Award in 1999, a career development award from the National Cancer Institute in 2000, was inducted into the Johns Hopkins Society of Scholars in 2008, and was honored to serve as UNC’s commencement speaker in December, 2009.
Training
M.D., Johns Hopkins School of Medicine 1990
Resident, Internal Medicine, Johns Hopkins 1990-3
Fellow, Medical Oncology, Johns Hopkins 1993-8
Sc.M., Clinical Investigations, Johns Hopkins School of Public Health 1994-8
Publications
2. Tzeng J, Mayer D, Richman AR, Lipkus I, Han PK, Valle CG, Carey LA, Brewer N. Women’s experiences with genomic testing for breast cancer recurrence risk. Cancer 2010 Mar 8 [Epub ahead of print].
3. Richman AR, Tzeng JP, Carey LA, Retel VP, Brewer NT. Knowledge of genomic testing among early-stage breast cancer patients. Psychooncology 2010 Mar 3 [Epub ahead of print].
4. Ellis M, Dehdashti F, Kommarreddy A, Andritsos L, Jamalabadi-Majidi S, Crowder R, Jeffe DB, Gao F, Carey L, Silverman P, Fleming GF, Dickler M, Marcom K. Lower dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: A randomized phase 2 study. JAMA 2009; 302(7):774-80.
5. Carey, LA. Targeted Chemotherapy? Platinum in BRCA1-dysfunctional breast cancer (editorial). J Clin Oncol, [Epub ahead of print]
6. Huber KE, Carey LA, Wazer DE. Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy. Semin Radiat Oncol. 2009; 19(4):204-10.
7. Bild A, Parker J, Gustafson A, Acharya C, Hoadley K, Anders, C, Marcom PK, Carey L, Nevins J, and Perou C. An Integration of Complementary Strategies for Gene Expression Analysis to Reveal Novel Therapeutic Opportunities for Breast Cancer. Breast Cancer Res. 2009 July; 28:11(4):R55. [epub ahead of print]
8. Mitchell K, Carey LA, Peppercorn J. Reporting of Race and Ethnicity in Breast Cancer Research: Room for Improvement. Breast Cancer Res Treat. 2009; 118(3):511-7.
9. Horton JK, Halle J, Ferraro M, Carey L, Moore, DT, Ollila D, Sartor CI. Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab:a phase II trial. Int J Rad Oncol Biol Physics 2009 June. [epub ahead of print].
10. Hu, Z, Fan C, Livasy C, Xe H, Oh D, Ewend M, Carey LA. Subramanian S, West R, Ikpatt F, Olopade O, van de Rejn M, Perou CM. A compact VEGF signature associated with distant metastases and poor outcomes. BMC Medicine 2009 June;(7):9-13.
11. Anders CK, Carey LA. Biology, Metastatic patterns and treatment of triple negative breast cancer. Clinical Breast Cancer June 2009; (1);9:S73-S81.
12. Hoskins JM, Carey LA, McLeod H. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 2009; (8):576-86. Review
13. Fredman SJ, Baucom DH, Gremore TM, Castellani AM, Kallman TA, Porter LS, Kirby JS, Dees EC, Klauber-Demore N, Peppercorn J, Carey LA. Quantifying the recruitment challenges in couple-based health interventions: Application to breast cancer. Psycho-Oncology 2009 June;18(6):667-73.
14. Olson JA Jr, Budd GT, Carey LA, Harris LA, Esserman LJ, Fleming GF, Marcom PK, Leight GS Jr, Giuntoli T, Commean P, Bae K, Luo J, Ellis MJ. J Am Coll Surg 2009 May;208(5):906-14;discussion 915-6.
15. Schneider BA, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA. Triple negative breast cancer: risk factors to potential targets. Clinical Cancer Res. 2008 Dec;14(24):8010-8.
16. Dees EC, O’Neil BH, Lindley CM, Collichio F, Carey LA, Humes E, Collins J, Riordan B, Ivanova A, Esseltine D, Schenkein D, Orlowski RZ. A Phase I and Pharmacologic Study of the Combination of Bortezomib and Pegylated Liposomal Doxorubicin in Patients with Refractory Solid Tumors. Cancer Chemotherapy and Pharmacology 2008 Dec;63(1):99-107.
17. Jerath MR, Kwan M, Kannarkat M, Mirakhur B, Carey L, Valgus J, Platts-Mills TA, Tarant TK. J Allergy Clin Immunol. 2009 Jan;123(1):260-2. Epub Nov 20 2008. No abstract available.
18. Irvin WJ, Carey LA. What is triple negative breast cancer (review). Eur J Cancer, 2008 Dec;44(18):2799-805. Epub Nov 2008
19. Anders C, Carey LA. Understanding and treating triple negative breast cancer (review). Oncology 2008 Oct;(11):1233-9;discussion 1239-40 1243.
20. Brewer NT, Edwards AS, O’Neill SC, Tzeng JP, Carey LA, Rimer BK. When genomic and standard test results diverge: Implications for breast cancer patients’ preference for chemotherapy. Breast Cancer Res Treat 2008 Sept; 117(1):25-9.
21. Ewend MG, Morris DE, Carey LA, Ladha AM, Brem S. Guidelines for the initial management of metastatic brain tumors: The role of surgery, radiosurgery, and radiation therapy. J NCCN 2008; 6(5):505-513.
22. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend MG, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP. Phase 2 Trial of Lapatinib for Brain Metastases in Patients with HER2-Positive Breast Cancer. J Clin Oncol 2008; 26(12):1993-9.
23. Van Emburgh BO, Hu JJ, Levine EA, Mosley LJ, Perrier ND, Freimanis RI, Allen GO, Rubin P, Sherrill GB, Shaw CS, Carey LA, Sawyer LR, Miller MS. Polymorphisms in CYP1B1, GSTM1, GSTT1, and GSTP1 and susceptibility to breast cancer. Oncol Rep 2008;19(5):1311-21.
24. Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer (review). Cancer Invest 2008;26(1):1-10.
25. Carey LA. Commentary on: Diallo-Dahnebrock R et al. Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy. Breast Diseases Quarterly 2008;18(4).
26. Wolff AC, Berry D, Carey LA, Colleoni M, Dowsett M, Ellis M, Garber JE, Mankoff D, Paik S, Pusztai L, Smith ML, Zujewski JA. Research issues affecting preoperative systemic therapy. J Clin Oncol 2008; 26(5):806-13.
27. Morrill EF, Brewer NT, O’Neill SC, Lillie SE, Dees EC, Carey LA, Rimer BK. The Interaction of Posttraumatic Growth and Posttraumatic Stress Symptoms in Predicting Depressive Symptoms and Quality of Life. Psychooncology,DOI: 2008;10.1002/pon.1313.
28. Van Emburgh BO, Hu JJ, Levine EA, Mosley LJ, Case LD, Lin HY, Knight SN, Perrier ND, Rubin P, Sherrill GB, Shaw CS, Carey LA, Sawyer LR, Allen GO, Milikowski C, Willingham MC, Miller MS. Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer. Mol Carcinog 2008;47(2):88-99.
29. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008;109(1):123-139.
30. O’Neill SC, Brewer NT, Lillie S, Morrill EF, Dees EC, Carey LA, Rimer BK. Women's Interest in Gene Expression Analysis for Breast Cancer Recurrence Risk. J Clin Oncol 2007;25(29):4628-34.
31. Hoadley KA, Weigman VJ, Fan C, Sawyer LR, He X, Troester MA, Sartor CI, Rieger-House T, Bernard PS, Carey LA, Perou CM. EGFR signaling varies with breast tumor subtype. BMC Genomics 2007Jul 31;8(1):258.
32. Morris SR and Carey LA. Genetic Profiling in Breast Cancer (review). Current Opinion in Oncology 2007;19(6):547-51.
33. Mayer EL, Carey LA, Burstein HA. Clincial Trial update:implications and management of residual disease after neoadjuvant therapy for breast cancer. Breast Cancer Research 2007;9:110.
34. Carey LA. The Carolina Breast Cancer Study: Race, breast cancer subtypes, and survival (review). American Journal of Hematology-Oncology 2007.
35. Bullitt E, Lin NU, Smith JK, Zeng D, Winer EP, Carey LA, Lin W, Ewend MG. Blood Vessel Morphological Changes as Visualized by MRA During Treatment of Brain Metastases. Radiology 2007;245:824-830.
36. Ewend MG, Brem S, Gilbert M, Goodkin R, Penar PL, Varia M, Cush S, Carey LA. Treatment of Single Brain Metastasis with Resection, Intracavity Carmustine-Polymer Wafers, and Radiation Therapy Is Safe and Provides Excellent Local Control. Clinical Cancer Research 2007;13(12):3637-41.
37. Morris SR and Carey LA. Molecular profiling in breast cancer. Rev Endocr Metab Disord 2007 Sept;8(3):185-98. Review
38. Carey LA, Dees EC, Sawyer LR, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clinical Cancer Research 2007;13:2329-2334.
39. Lillie SE, Brewer NT, O’Neill SC, Morrill EF, Dees EC, Carey LA, Rimer BK. Retention and use of breast cancer recurrence risk information from genomic tests: The role of health literacy. Cancer Epidemiology Biomarkers and Prevention 2007;16(2):249-55.
40. Finnegan TJ and Carey LA. Gene expression analysis and the basal-like breast cancer subtype (review). Future Oncol 2007;3(1):55-63.
41. Morris SR and Carey LA. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer (review). Oncology 2006; 20:1763-1771.
42. Carey LA and Burstein H. Treatment of a premenopausal patient with basal-like breast cancer. Oncology Consultations 2006;3:13-20.
43. Ryan JL, Kaufmann WK, Oglesbee SE, Raab-Traub N, Carey LA, Gulley ML. Clonal evolution of lymphoblastoid cell lines. Laboratory Investigations 2006; 86:1193-1200.
44. Bullitt E, Lin N, Ewend M, Zeng D, Winer E, Carey L, Smith JK. Tumor Therapeutic Response and Vessel Tortuosity: Preliminary Report in Metastatic Breast Cancer. Medical image computing and computer-assisted intervention 2006;4191:561-568.
45. Kelly H, Kimmick G, Dees EC, Collichio F, Gatti L, Sawyer L, Ivanova A, Dressler L, Graham ML, Carey LA. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide. Clin Breast Cancer 2006;7(3):237-243.
46. Kaufmann WK, Filatov L, Oglesbee SE, Simpson Da, Lotano MA, McKeen HD, Sawyer LR, Moore DT, Millikan RC, Cordeiro-Stone M, Carey LA. Radiation clastogenesis and cell cycle checkpoint function as markers of ataxia telangiectasia and breast cancer. Carcinogenesis 2006 Dec;27(12): 2519-27.
47. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MCU, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes and survival in the Carolina Breast Cancer Study. JAMA 2006; 295(21):2492-502.
48. Hu Z, Fan C, Oh D, Marron JS, He X, Qaquish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend M, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Orrico AR, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS, Perou CM. The Molecular Portraits of Breast Tumors Are Conserved Across Microarray Platforms. BMC Genomics 2006;7:96.
49. Klauber-Demore N, Ollila DW, Moore DT, Livasy C, Calvo BF, Kim HJ, Dees EC, Sartor CI, Sawyer LR, Graham M, Carey LA. Size of Residual Lymph Node Metastases Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients is Prognostic. Ann Surg Onc 2006;13(5):685-91.
50. Neuman H, Carey LA, Ollila DW, Livasy C, Calvo BF, Meyer AA, Kim HJ, Meyers MO, Dees EC, Collichio FA, Sartor CI, Moore DT, Sawyer LR, Frank J, Klauber-DeMore N. Axillary Lymph Node Count is Lower after Neoadjuvant Chemotherapy. American Journal of Surgery 2006;191(6):827-9.
51. Oh DS, Troester MA, Usary J, Hu Z, He X, Fan C, Wu J, Carey LA, Perou CM. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 2006;24(11):1656-1664.
52. Carrizosa DR, Carey LA. Adjuvant systemic therapy in young women. Breast Dis 2005;23:67-72.
53. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer- ready for clinical application? J Clin Oncol 2005;23(29):7350-60.
54. Carrizosa DR, Carey LA. Adjuvant Treatment Decisions in Breast Cancer: Where Does the Recurrence Score Fit In? (Commentary). American Journal of Oncology Review 2005;4(10):6-10.
55. Weigelt B, Hu Z, He X, Livasy C, Carey LA, Ewend MG, Glas AM, Perou CM, van’t Veer LJ. Molecular Portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Research 2005;65(20):9155-9158.
56. Carey LA. Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes (commentary). Breast Diseases: A Year Book Quarterly, 2005.
57. Ewend MG, Elbabaa S, Carey LA. Current treatment paradigms for the management of patients with brain metastases (review). Neurosurgery 2005; 57(5):S4-66-4-77.
58. Carey LA. Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer (review). Breast Diseases: A Year Book Quarterly, 2005.
59. Ollila DW, Neuman HB, Sartor C, Carey LA, Klauber-Demore N. Lymphatic Mapping and Sentinel Lymphadenectomy Prior to Neoadjuvant Chemotherapy in Patients with Large Breast Cancers. American Journal of Surgery 2005; 190(3):371-375.
60. Carey LA, Metzger R, Dees EC, Collichio F, Sartor CI, Ollila DW, Klauber-Demore N, Halle J, Sawyer L, Amamo A, Moore DT, Graham ML. Residual tumor assessed by the revised American Joint Commission on Cancer (AJCC) staging system provides a simple prognostic index for breast cancer after neoadjuvant chemotherapy. J National Cancer Institute 2005; 97:1137-1142.
E-mail: Lisa_Carey@med.unc.edu
Telephone: (919) 966-4431
FAX: (919) 966-6735
Address: 3009 Old Clinic Bldg. Chapel Hill, NC 27599-7305
